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Abstract
Galiellalactone is a potent and specific inhibitor of STAT3 signaling which has been shown to possess growth inhibitory
effects on prostate cancer cells expressing active STAT3. In this study we aimed to investigate the effect of galiellalactone on
prostate cancer stem cell-like cells. We explored the expression of aldehyde dehydrogenase (ALDH) as a marker for cancer
stem cell-like cells in different human prostate cancer cell lines and the effects of galiellalactone on ALDH expressing
(ALDH+) prostate cancer cells. ALDH+ subpopulations were detected and isolated from the human prostate cancer cell lines
DU145 and long-term IL-6 stimulated LNCaP cells using ALDEFLUORH assay and flow cytometry. In contrast to ALDH2 cells,
ALDH+ prostate cancer cells showed cancer stem cell-like characteristics such as increased self-renewing and colony
forming capacity and tumorigenicity. In addition, ALDH+ cells showed an increased expression of putative prostate cancer
stem cell markers (CD44 and integrin a2b1). Furthermore, ALDH+ cells expressed phosphorylated STAT3. Galiellalactone
treatment decreased the proportion of ALDH+ prostate cancer cells and induced apoptosis of ALDH+ cells. The gene
expression of ALDH1A1 was downregulated in vivo in galiellalactone treated DU145 xenografts. These findings emphasize
that targeting the STAT3 pathway in prostate cancer cells, including prostate cancer stem cell-like cells, is a promising
therapeutic approach and that galiellalactone is an interesting compound for the development of future prostate cancer
drugs.
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Introduction
Prostate cancer is the most commonly diagnosed tumor among
men and there is a great need of novel therapies against castration
resistant prostate cancer [1]. According to the cancer stem cell
theory, only a small subset of cancer cells are capable of tumor
growth and recurrence [2,3]. Prostate cancer stem cells appear to
be resistant to conventional cancer therapy and may therefore be
involved in advanced prostate tumors and cause relapse and
metastasis [4,5]. Prostate tumors comprise of only 0.1% stem cells
but failure to eradicate this cell sub-population may cause
regeneration of the tumor and drug resistance and in order to
prevent recurrence it is important to target all cell types in the
tumor [5,6,7,8]. Novel targeted therapies that target prostate
cancer stem cell-like cells are highly warranted.
In the search for specific markers of cancer stem cells, aldehyde
dehydrogenase (ALDH) has shown promise as such a marker in
different cancers including bladder cancer [9], lung cancer [10],
head and neck squamous cell carcinoma [11], breast cancer [12]
and prostate cancer [13,14]. A high expression of ALDH in
prostate cancer stem cells has been shown to be positively
correlated with Gleason score and inversely correlated with patient
survival in prostate cancer patients [13]. High ALDH activity has
successfully been used to identify tumor initiating prostate cancer
cells and metastases [14].
Signal transducer and activator of transcription 3 (STAT3) is an
important transcription factor in many cancer types and it has been
shown to be involved in drug resistance and to have anti-apoptotic
effects in prostate cancer cells. Constitutively active STAT3
contributes to oncogenesis through upregulation of genes coding
for anti-apoptotic proteins, cell cycle regulators and angiogenesis
stimulators, leading to increased survival and uncontrolled growth
of cancer cells [15]. STAT3 expression is suggested to be correlated
to malignant potential and metastatic behavior in prostate cancer
[16,17]. Furthermore, gene expression analysis of prostate cancer
stem cells has revealed a pro-inflammatory phenotype and that the
JAK/STAT3-signaling pathway is active in this cell population
[18]. Several studies highlight STAT3 as a valid target for the
development of new drugs for prostate cancer and other
malignancies [19,20,21]. We have shown, both in vivo and in vitro,
that the STAT3inhibitor galiellalactone possessesgrowth inhibitory
effects on prostate cancer cells expressing active, phosphorylated
STAT3 [22]. Galiellalactone is a metabolite produced by thefungus
Galiella rufa and it has been synthetically produced as previously
described [23]. Galiellalactone is a highly potent and selective
inhibitor of IL-6 signaling through STAT3, and is believed to
inhibit STAT3 signaling by blocking the binding of activated
STAT3 to DNA [24].
In this study we aimed to explore the expression of ALDH as a
marker for cancer stem cell-like cells in different human prostate
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22118cancer cell lines and the effects of the STAT3 inhibitor
galiellalactone on ALDH expressing prostate cancer cells.
Materials and Methods
Cell culture
The human prostate cancer cell lines DU145, LNCaP (from the
American Type culture Collection, [ATCC]) and long-term
interleukin-6 (IL-6) stimulated LNCaP cells (LNCaP-IL6 cells)
[25] were used. The cells were cultured in RPMI 1640 medium
supplemented with 10% FBS and 1% penicillin-streptomycin.
LNCaP-IL6 cells were maintained in the above medium
supplemented with IL-6 (5 ng/ml; Sigma-Aldrich, St. Louis,
MO). All cells were incubated at 37uC in a humidified atmosphere
of 95% O2 and 5% CO2. Cells were used at low passages and not
cultured for more than two-three months. Cells were routinely
tested for mycoplasma and found free of mycoplasma. Cell identity
was not authenticated by the authors. Galiellalactone was
prepared by synthesis as previously described [23].
ALDEFLUOR assay and cell sorting
Prostate cancer cells (DU145, LNCaP and LNCaP-IL6) were
subjected to ALDEFLUORH assay (StemCell Technologies,
Aldagen, Inc., Durham, NC) followed by flow cytometry to detect
cells with high activity of ALDH (ALDH+). The active reagent
BODIPYH-aminoacetaldehyde was added to the cells which was
converted by ALDH to the fluorescent BODIPYH-aminoacetate.
The ALDH inhibitor diethylaminobenzaldehyde (DEAB) was used
as a negative control. DU145 and LNCaP-IL6 cells were treated
with 0–50 mM galiellalactone for 24 h and the proportion of
ALDH+ was analyzed with ALDEFLUORH assay. DU145 and
LNCaP-IL6 cells were subjected to cell sorting based on the
ALDH activity using the ALDEFLUORH assay. ALDH+ and
ALDH2 cells were sorted using the BD FACSAria cell sorter (BD
Biosciences, San Jose, CA). Non-viable cells were excluded using
7-Amino-actinomycin D staining. ALDH+ and ALDH2 subpop-
ulations from DU145 and LNCaP-IL6 cells were re-plated after
sorting and analysed with ALDEFLUORH assay after one week in
culture in order to investigate their self-renewing capacity.
Cytospin and immunohistochemistry
ALDH+ and ALDH2 cells sorted from DU145 and LNCaP-
IL6 cells were directly subjected to cytospin or replated and
treated with galiellalactone, trypsinized and washed in PBS before
subjected to cytospin. The cell suspension was placed in a cytospin
funnel clamped to a glass slide and spun at 800 rpm for 2 minutes.
The slides were air dried, fixed in 4% paraformaldehyde for
10 minutes and permeabilized with 1% Triton-x in Tris buffer,
pH 7.6 for 1 h. The slides were subjected to immunohistochem-
istry using Dako Autostainer Plus and EnVision
TM+ kit (Dako).
The antibodies used were CD44 (BD Pharmingen), integrin a2b1
(Abcam), CD133, (c-PARP), p-STAT3 and p-NF-kB p65 (Cell
Signaling Technology).
Apoptotic cells
Sorted ALDH+ and ALDH2 cells from DU145 and LNCaP-
IL6 cells were treated with 25 mM galiellalactone for 24 h,
subjected to cytospin and stained for the apoptotic marker c-
PARP. A minimum of 500 cells were counted from two separate
experiments and the number of labeled c-PARP cells were
calculated relative the total number of cells. The number of
apoptotic cells was expressed as a fraction of the total number of
cells.
WST-1 cell proliferation assay
WST-1 proliferation assay was performed to study the effect of
galiellalactone on proliferation and viability of ALDH+ and
ALDH2 cells sorted from DU145 and LNCaP-IL6 cells. ALDH+
and ALDH2 cells were cultured in 96-well plates at the density of
2 000 cells/well in 200 ml of medium. Cells were allowed to set for
24 h. The cells were treated with 0–50 mM galiellalactone for
24 h. Samples were made in triplicate. 20 ml WST-1 solution
(Roche Applied Science, Mannheim, Germany) was added per
well and incubated at 37uC for 4 h. The absorbance of each well
was measured using a scanning multi-well spectrophotometer,
ELISA reader at a wavelength of 450 nm and reference
wavelength of 690 nm. The results are presented as per cent of
untreated control cells.
Cloning efficiency analysis
ALDH+ and ALDH2 cells sorted from DU145 and LNCaP-
IL6 cells were cultured in 24-well plates at a density of 200 cells
per well. The colony formation was measured after one
week. Clones were visualized with Crystal Violet staining and
counted. The cloning efficiency was calculated as percent of
plated cells.
Prostate tumor xenograft model
Six to eight-week old male nude NMR1 mice were kept on a
12 h light-dark cycle with access to food and water ad libitum.
Experimental procedures were approved and carried out
according to the guidelines set by the Malmo ¨-Lund Ethical
Committee for use and care of laboratory animals. Nude mice
with subcutaneous DU145 prostate cancer cell xenografts (1610
6
DU145 cells) were subjected to daily i.p. injections of galiella-
lactone (1 mg/kg) or vehicle for three weeks [22]. After 21 days
the mice were sacrificed by ketamin injection (50 mg/kg)
followed by cervical dislocation and the xenografts were dissected
out and immediately snap frozen in liquid nitrogen and stored at
280uC until further processing. Total RNA was isolated from
frozen DU145 xenografts from untreated mice (n=6) and mice
treated with 1 mg/kg galiellalactone per day for three weeks
(n=3).
Tumorigenicity assay
Freshly sorted ALDH+ and ALDH2 populations of DU145
and LNCaP-IL6 cells were suspended in serum free medium/
Matrigel (BD Biosciences) mixture (1:1 volume). Six to eight-
w e e ko l dm a l en u d eN M R 1m i c e( n = 5 )w e r ei n j e c t e dw i t h
ALDH+ or ALDH2 cells subcutaneously in the right and left
flank of the mouse, respectively, in concentrations 10 000 or
100 000 cells per injection site. The tumor growth was
monitored during the whole experiment. Tumor size was
measured after six weeks using a caliper and the tumor volume
(ml) was calculated by the formula length (mm)6width6
height60.5632. The mice were sacrificed with isoflurane and
cervical dislocation after 6 week.
Quantitative real-time PCR
The gene expression of CD44, CD133, integrin a2 and
ALDH1A1 was investigated with quantitative real-time PCR (q-
PCR). Cells were harvested by brief centrifugation directly after
cell sorting or after treatment with galiellalactone, and pellets were
stored at 280uC until RNA isolation. Total RNA was isolated
using QIAshredder spin columns, and further mRNA enrichment
and additional washing was performed using the RNeasy kit
(Qiagen Sciences). To exclude DNA contamination, samples were
Galiellalactone and ALDH+ Prostate Cancer Cells
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(Promega). Complementary DNA (cDNA) was synthesized using
random hexamers and reverse transcriptase Superscript II
(Invitrogen). Total RNA was isolated from DU145 xenografts
using Trizol (Invitrogen). Five micrograms of total RNA was
obtained for the cDNA synthesis using a HPLC purified Oligo
dTprimer with a T7 sequence.
Quantitative real-time PCR was carried out using 6–20 ng
cDNA, 250 nM forward and reverse primer in 26SYBR Green
PCR Master Mix (Applied Biosystems) in a 25 ml reaction. The
cycling conditions were: 10 min at 95uC to activate the enzyme,
then 40 cycles of 95uC for 15 sec and 60uC for 60 sec. Relative
expression levels were quantified by the comparative Ct method
[26] and normalized to the expression of the three most stable
internal control genes (HPRT, UBC, and YWHAZ), selected by
geNorm software analysis as the most stable reference genes.
Primers sequences were as previously reported: HPRT, UBC and
YWHAZ [26], ALDH1A1 [27], CD133 [28], CD44 [29], and
Figure 1. ALDH expressing cells in prostate cancer cell lines. DU145, LNCaP and LNCaP-IL6 cells were subjected to ALDEFLUORH assay in
order to identify cells with high ALDH expression (ALDH+). The ALDH inhibitor DEAB was used as a negative control (left panel). The cells without
inhibitor shifted to the right were considered ALDH+ cells (right panel).
doi:10.1371/journal.pone.0022118.g001
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checked for specificity before use.
Statistics
Results are expressed as the mean 6 standard error of the mean
(SEM). Statistical analysis of data was performed by Dunnett’s test
or Student’s t test using JMP software (SAS Institute Inc, Cary,
NC). The results were considered to be statistically significant at
p,0.05.
Results
ALDH expression in prostate cancer cell lines
DU145, LNCaP and LNCaP-IL6 cells were investigated for
their ALDH activity using the ALDEFLUORH assay and flow
cytometry. In DU145 cells 2.6260.23% of the cells were
expressing high ALDH activity (ALDH+), 2.8460.5% of the
LNCaP-IL6 cells were ALDH+ and in LNCaP cells 0.5760.34%
cells showed ALDH activity (n=3–4) (Figure 1).
Figure 2. Characteristics of ALDH+ and ALDH2 cells. ALDH+ cells show stem cell-like characteristics in terms of increased colony forming
capacity and tumorigenicity. A. Clonogenic assay. 200 cells/well were seeded and colonies were counted after 1 week. Clonogenicity was calculated
as percent colonies formed in relation to cells seeded (n=2; p,0.05). B. Tumorigenicity assay. Tumor take after subcutaneous injections of 10 000 or
100 000 cells of freshly sorted ALDH+ and ALDH2 cells from DU145 and LNCaP-IL6 (n=5). C. Tumor size of ALDH+ and ALDH2 cell xenografts after 6
weeks (n=5). ALDH+ cell tumors from 100 000 cells injected subcutaneously were significantly larger than the ALDH2 cell tumors for both DU145
cells (p=0.0002) and LNCaP-IL6 cells (p=0.0077).
doi:10.1371/journal.pone.0022118.g002
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The characteristics of ALDH+ and ALDH2 cell populations
isolated from DU145 and LNCaP-IL6 cells were investigated with
respect to self-renewing and colony-forming capacity and
tumorigenicity.
The sorted ALDH+ and ALDH2 subpopulations from DU145
and LNCaP-IL6 cells were re-plated after sorting and analysed
with ALDEFLUORH assay after one week in culture in order to
investigate their self-renewing capacity. After one week in culture
small populations of ALDH+ cells were detected among the
ALDH2 DU145 and ALDH2 LNCaP-IL6 cells (0.2660,24%
and 0.3660.05%, respectively, n=2). However, after one week in
culture after sorting, the ALDH+ LNCaP-IL6 and ALDH+
DU145 cell cultures re-established their parental phenotype and
constituted a population resembling that of the original parental
cell line with 2.2461.23% and 1.2460.14% ALDH+ cells,
respectively (n=2).
The colony-forming efficiency was significantly greater in
ALDH+ cells compared to ALDH2 cells from both LNCaP-IL6
and DU145 cells (Figure 2A). The ALDH+ clones formed were
visibly larger than the ALDH2 clones. The tumorigenicity of
ALDH+ and ALDH2 cells freshly sorted from DU145 and
LNCaP-IL6 cells was investigated by injecting 10 000 or 100 000
cells subcutaneously into the flank of nude mice (n=5) and tumor
growth was monitored weekly. ALDH+ cells showed a greater
tumor forming capacity compared to ALDH2 cells from both
DU145 and LNCaP-IL6 cells and the discovery of palpable
tumors was delayed in ALDH2 cells (Figure 2B). The ALDH+
tumors were significantly larger than the ALDH2 tumors after six
weeks (Figure 2C).
Expression of various biomarkers related to stem cells
The expression of various biomarkers putatively related to
cancer stem cells were investigated in freshly sorted ALDH+ and
ALDH2 fractions of DU145 and LNCaP-IL6 cells (Figure 3).
CD44 was detected by immunohistochemistry in both ALDH+
and ALDH2 cells sorted from DU145 cells and the expression
was more intense in ALDH+ cells compared to ALDH2 cells
(Figure 3A). CD44 immunostaining was observed in most ALDH+
LNCaP-IL6 cells in contrast to ALDH2 LNCaP-IL6 cells where
fewer cells were stained for CD44. Integrin a2b1 was expressed in
both ALDH+ and ALDH2 cells sorted from DU145 cells and the
Figure 3. Expression of cancer stem cell related markers. A. Freshly sorted ALDH+ and ALDH2 cells from DU145 and LNCaP-IL6 cells were
subjected to cytospin and stained for CD44, integrin a2b1, p-STAT3 and p-NF-kB p65. B. The relative mRNA expression of CD44 and integrin a2i n
ALDH+ and ALDH2 cells freshly sorted from DU1145 and LNCaP-IL6 cells.
doi:10.1371/journal.pone.0022118.g003
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ALDH2 cells. Integrin a2b1 was expressed in ALDH+ cells from
LNCaP-IL but only a few cells expressed integrin a2b1 in the
ALDH2 cells. CD133 was not detectable in ALDH+ and ALDH2
cells from both DU145 and LNCaP-IL6 cells. The expression of
active STAT3 and NF-kB was investigated in ALDH+ and
ALDH2 fractions of DU145 and LNCaP-IL6 cells (Figure 3A).
Increased p-STAT3 expression was observed in ALDH+ cells
compared to ALDH2 cells from both cell lines. P-NF-kB p65 was
detected in ALDH+ DU145 cells but not in ALDH2 DU145,
ALDH+ LNCaP-IL6 or ALDH2 LNCaP-IL6 cells.
The gene expression of CD44, integrin a2 and CD133, was
investigated with quantitative -PCR. (Figure 3B). mRNA expres-
sion levels of CD44 and integrin a2 was increased in ALDH+ cells
compared to ALDH2 cells from LNCaP-IL6 cells. There was no
difference in the mRNA level of CD44 and integrin a2 in ALDH+
and ALDH2 cells from DU145. mRNA levels of CD133 was not
detectable in ALDH+ and ALDH2 cells from both DU145 and
LNCaP-IL6 cells.
Galiellalactone decreases the proportion of ALDH+ cells
DU145 and LNCaP-IL6 cells were treated with galiellalactone
(5, 10, 25 or 50 mM) for 24 h and subjected to ALDEFLUORH
assay in order to investigate the effect of galiellalactone on the
proportion of ALDH+ cells compared to vehicle. Galiellalactone
decreased the proportion of ALDH+ cells of both DU145 and
LNCaP-IL6 cells in a dose dependent manner (Figure 4A).
Incubation with galiellalactone at 25 mM for 24 h significantly
decreased the proportion of ALDH+ DU145 cells by 51%
(p=0.0013) and the proportion ALDH+ LNCaP-IL6 cells by
75% (p=0.0441).
Galiellalactone decreases the ALDH1A1 mRNA expression
in DU145 xenografts
Mice with DU145 xenografts were treated with vehicle or
1 mg/kg galiellalactone daily for three weeks, the tumors were
harvested and the gene expression was analyzed. The mRNA
expression of ALDH1A1 was 4.6 times lower in galiellalactone
treated xenografts compared to controls (Figure 4B).
Figure 4. Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo. A.
DU145 and LNCaP-IL6 cells were treated with galiellalactone (5–50 mM) for 24 h and subjected to ALDEFLUORH assay. The proportion of ALDH+ cells
significantly decreased due to galiellalactone treatment in a dose dependent manner. The proportion of ALDH+ cells is expressed as mean 6 SEM
(n=2–4). The proportion of ALDH+ DU145 cells were significantly decreased by galiellalactone at the concentrations 10 mM (p=0.0060), 25 mM
(p=0,0013) and 50 mM galiellalactone (p,0,0001). The proportion of ALDH+ LNCaP-IL6 cells was significantly decreased by galiellalactone at the
concentrations 25 mM (p=0.0441) and 50 mM (p=0.0445). B. Relative mRNA expression of ALDH1A1 in DU145 xenografts in mice treated with 1 mg/
kg/day galiellalactone for three weeks. Control mice received vehicle. The relative mRNA expression of ALDH1A1 was reduced in galiellalactone
treated mice compared to control (0.13960.107 and 0.64460.161, respectively, p=0.07; n=3–6).
doi:10.1371/journal.pone.0022118.g004
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apoptosis of ALDH+ cells
Sorted ALDH+ and ALDH2 cells from DU145 and LNCaP-
IL6 cells were treated with 25 mM galiellalactone for 24 h and
immunostained for the apoptotic marker c-PARP (Figure 5A). An
increased number of c-PARP positive cells were detected in
galiellalactone treated ALDH+ and ALDH2 cells compared to
untreated cells (Figure 5A). The apoptotic response in ALDH+
and ALDH2 cells sorted from DU145 and LNCaP-IL6 cells
treated with 25 mM galiellalactone for 24 h was quantified by
counting c-PARP expressing cells (Figure 5B). Treatment with
galiellalactone significantly increased the amount of c-PARP
expressing cells in ALDH+ DU145, ALDH+ LNCaP-IL6 and
ALDH2 LNCaP-IL6 cells compared to untreated controls. The
ALDH+ cells showed a greater apoptotic response to galiellalac-
tone compared to ALDH2 cells as measured by c-PARP
expression. However, this difference was not significant
(p=0.059 for DU145 cells and p=0.119 for LNCaP-IL6 cells,
n=2). The effect of galiellalactone on the viability and
proliferation of ALDH+ and ALDH2 cells was investigated
(Figure 5C). Galiellalactone decreased the proliferation of both
ALDH+ and ALDH2 cells isolated from DU145 and LNCaP-IL6
Figure 5. Galiellalactone induces apoptosis and inhibits proliferation of ALDH+ prostate cancer cells. A. ALDH+ and ALDH2 cells sorted
from DU145 and LNCaP-IL6 cells were treated with 25 mM galiellalactone for 24 h. Apoptotic cells were detected by c-PARP staining. B. Quantification
of c-PARP stained apoptotic cells in ALDH+ and ALDH2 cells sorted from DU145 and LNCaP-IL6 cells and treated with 25 mM galiellalactone for 24 h.
Treatment with galiellalactone significantly increased the amount of c-PARP expressing cells in ALDH+ DU145, ALDH+ LNCaP-IL6 and ALDH2 LNCaP-
IL6 cells compared to untreated controls (p=0.019, 0.035 and 0.009 respectively; n=2). The difference in apoptotic response between galiellalactone
treated ALDH+ and ALDH2 cells from DU145 and LNCaP-IL6 cells was not significant (p=0.059 and p=0.119, respectively; n=2). C. Galiellalactone
decreased the viability of ALDH+ and ALDH2 cells sorted from DU145 and LNCaP-IL6 cells. The ALDH+ DU145 cells were significantly more sensitive
to galiellalactone compared to the corresponding ALDH2 cells at 5 mM (p=0.0017), 10 mM (p=0.0010), 25 mM (p=0.0019) and 50 mM (p=0.0025).
Results are presented as mean per cent of untreated control (n=2).
doi:10.1371/journal.pone.0022118.g005
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were significantly more sensitive to galiellalactone treatment than
the ALDH2 cells sorted from DU145 cells. However, there was
no significant difference in the sensitivity to galiellalactone
between ALDH+ and ALDH2 LNCaP-IL6 cells.
Discussion
Prostate cancer stem cells are shown to be androgen
independent and lack expression of a functional androgen receptor
[6,18] which renders them immune to androgen deprivation
therapy (ADT). In a mouse model of prostate cancer, increased
expression of stem cell markers was observed after ADT [31].
Furthermore, cancer stem cells are resistant to current chemo-
therapy and ALDH expressing cancer stem cells have shown
resistance to and enrichment by paclitaxel treatment [32]. The
cancer stem cell characteristics such as slow growth, multidrug
resistance, enhanced DNA-repair, high expression of anti-
apoptotic proteins [33], and in prostate cancer the lack of
response to ADT, make these cells very difficult to target with
conventional prostate cancer therapy. New therapeutic modalities
must therefore be developed, in order to target both the tumor
bulk and the cancer stem cells.
In the present study we identified cancer stem cell-like
subpopulations in cultured prostate cancer cell lines which
responded to treatment with the STAT3 inhibitor galiellalactone.
A small fraction (2–4%) of the cell line populations showed high
ALDH activity. These ALDH+ cells revealed stem cell-like
characteristics such as increased colony forming and self-renewing
capacity and high tumorigenicity as well as expression of putative
prostate cancer stem cell markers. These cells responded to
treatment with galiellalactone.
The capability of reconstituting a heterogenous mass is a
definition of cancer stem cells, and we found that isolated ALDH+
prostate cancer cells were capable of self-renewal and re-
establishment of the parental cell line and possessed high
tumorigenicity in vivo and in vitro. The ALDH+ population of
LNCaP-IL6 cells had a high expression of the putative prostate
cancer stem cells markers CD44 and integrin a2b1 [34] compared
to the ALDH2 population. However, we did not detect CD133
expression in the ALDH+ or ALDH2 prostate cancer cells. This
is in agreement with the recent study by Pfeiffer and Schalken [35]
suggesting that CD133 is not a marker for stem cells in prostate
cancer cell lines. Increased JAK/STAT3 and NF-kB activity is
expressed in stem cells and tumor initiating stem-like cells in
prostate cancer [18,36] and our findings of active STAT3 and NF-
kB in ALDH+ cells is in accordance with this suggestion. Taken
together, our results, and others [14], indicate that ALDH
expression can be a means of identifying cancer stem cell-like
cells in prostate cancer.
The cancer stem cell-like ALDH+ population was greater in
long term IL-6 stimulated LNCaP cells compared to LNCaP cells
supporting the view that prostate cancer stem cells show a pro-
inflammatory phenotype [18,37]. Gene expression profiling of
prostate cancer stem cells show that the STAT3 signaling pathway
is overexpressed in these cells [18] and several studies point to
STAT3 as a target for therapeutic intervention in tumor stem cells
[38,39]. This is in line with our finding that the ALDH+ stem cell-
like cells from prostate cancer cell lines expressed active STAT3
and that these ALDH+ cells responded to the STAT3 inhibitor
galiellalactone, which has previously been shown to induce
apoptosis of prostate cancer cells with constitutive expression of
active STAT3 [22]. The dose-response related decrease of the
proportion of ALDH+ cells in the DU145 and LNCaP-IL6 cell
populations and induction of apoptosis of these cells upon
galiellalactone treatment suggest that these cancer stem cell-like
cells are sensitive to STAT3 inhibition. Noteably, DU145
xenografts from galiellalactone treated mice showed reduced gene
expression of ALDH1A1 compared to untreated DU145 xenografts
indicating that galiellalactone may target prostate cancer stem cell-
like cells also in vivo. We have previously showed that the
expression of the STAT3 related genes BCL2L1 and MCL1 were
down-regulated by galiellalactone further confirming the STAT3
inhibitory effect of the drug in vivo [22].
Other natural products besides galiellalactone have been shown
to inhibit cancer stem cells. Sesquiterpene lactone parthenolide
and curcumin are cytotoxic to cancer stem cells and target the cells
by inhibiting the activity of NF-kB and STAT3 [40,41]. Targeting
the STAT3 pathway in prostate cancer stem cell-like cells with
natural product derived compounds may be a promising
therapeutic approach for the development prostate cancer drugs.
In conclusion, prostate cancer cell lines contained ALDH+
subpopulations with stem cell-like characteristics which expressed
phosphorylated STAT3. These subpopulations were clearly
inhibited by the STAT3 inhibitor galiellalactone. These findings
emphasize that targeting the STAT3 pathway in prostate cancer
cells, including prostate cancer stem cell-like cells, may be a novel
potent treatment strategy in patients with advanced prostate
cancer resistant to ADT and cytotoxic therapy and that
galiellalactone is an important compound for studying STAT3
signaling in prostate cancer and a potential starting point for the
development of future prostate cancer drugs.
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